137 related articles for article (PubMed ID: 1381849)
1. Heparin cofactor II deficiency in the elderly: comparison with antithrombin III.
Kario K; Matsuo T; Kobayashi H
Thromb Res; 1992 Jun; 66(5):489-98. PubMed ID: 1381849
[TBL] [Abstract][Full Text] [Related]
2. Preferential consumption of heparin cofactor II in disseminated intravascular coagulation associated with acute promyelocytic leukemia.
Kario K; Matsuo T; Kodama K; Katayama S; Kobayashi H
Thromb Res; 1992 May; 66(4):435-44. PubMed ID: 1412208
[TBL] [Abstract][Full Text] [Related]
3. Lipid-related hemostatic abnormalities in the elderly: imbalance between coagulation and fibrinolysis.
Kario K; Matsuo T
Atherosclerosis; 1993 Nov; 103(2):131-8. PubMed ID: 8292090
[TBL] [Abstract][Full Text] [Related]
4. Lower androgenicity is associated with higher plasma levels of prothrombotic factors irrespective of age, obesity, body fat distribution, and related metabolic parameters in men.
De Pergola G; De Mitrio V; Sciaraffia M; Pannacciulli N; Minenna A; Giorgino F; Petronelli M; Laudadio E; Giorgino R
Metabolism; 1997 Nov; 46(11):1287-93. PubMed ID: 9361687
[TBL] [Abstract][Full Text] [Related]
5. Heparin cofactor II deficiency in renal allograft recipients: no correlation with the development of thrombosis.
Toulon P; Moulonguet-Doleris L; Costa JM; Aiach M
Thromb Haemost; 1991 Jan; 65(1):20-4. PubMed ID: 2024235
[TBL] [Abstract][Full Text] [Related]
6. Gender differences of disturbed hemostasis related to fasting insulin level in healthy very elderly Japanese aged > or = 75 years.
Kario K; Matsuo T; Kobayashi H; Sakata T; Miyata T; Shimada K
Atherosclerosis; 1995 Aug; 116(2):211-9. PubMed ID: 7575776
[TBL] [Abstract][Full Text] [Related]
7. An antithrombin III assay based on factor Xa inhibition provides a more reliable test to identify congenital antithrombin III deficiency than an assay based on thrombin inhibition.
Demers C; Henderson P; Blajchman MA; Wells MJ; Mitchell L; Johnston M; Ofosu FA; Fernandez-Rachubinski F; Andrew M; Hirsh J
Thromb Haemost; 1993 Mar; 69(3):231-5. PubMed ID: 8470046
[TBL] [Abstract][Full Text] [Related]
8. Antithrombin-III assay without influence of heparin cofactor II.
Enomoto M; Tanimizu I; Sakuragawa N
Thromb Res; 1990 Mar; 57(5):729-36. PubMed ID: 2339367
[TBL] [Abstract][Full Text] [Related]
9. Heparin cofactor II: experimental approach to a new assay and clinical results.
Vinazzer H; Stocker K
Thromb Res; 1991 Feb; 61(3):235-41. PubMed ID: 2028443
[TBL] [Abstract][Full Text] [Related]
10. Purification and biological property of heparin cofactor II: activation of heparin cofactor II and antithrombin III by dextran sulfate and various glycosaminoglycans.
Yamagishi R; Niwa M; Kondo S; Sakuragawa N; Koide T
Thromb Res; 1984 Dec; 36(6):633-42. PubMed ID: 6084876
[TBL] [Abstract][Full Text] [Related]
11. Assessment of interference by heparin cofactor II in the DuPont aca antithrombin-III assay.
Hortin GL; Tollefsen DM; Santoro SA
Am J Clin Pathol; 1988 Apr; 89(4):515-7. PubMed ID: 3354504
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of thrombin by antithrombin III and heparin cofactor II in vivo.
Liu L; Dewar L; Song Y; Kulczycky M; Blajchman MA; Fenton JW; Andrew M; Delorme M; Ginsberg J; Preissner KT
Thromb Haemost; 1995 Mar; 73(3):405-12. PubMed ID: 7545318
[TBL] [Abstract][Full Text] [Related]
13. Heparin cofactor II levels are increased by the use of combined oral contraceptives.
Mackie IJ; Segal H; Burren T; Gallimore M; Walshe KJ; Robinson G; Machin SJ
Blood Coagul Fibrinolysis; 1990 Dec; 1(6):647-51. PubMed ID: 2133244
[TBL] [Abstract][Full Text] [Related]
14. Antithrombin III and heparin cofactor II in patients with chronic renal failure undergoing regular hemodialysis.
Toulon P; Jacquot C; Capron L; Frydman MO; Vignon D; Aiach M
Thromb Haemost; 1987 Jun; 57(3):263-8. PubMed ID: 3660328
[TBL] [Abstract][Full Text] [Related]
15. Elevated levels of thrombin-heparin cofactor II complex in plasma from patients with disseminated intravascular coagulation.
Andersson TR; Sie P; Pelzer H; Aamodt LM; Nustad K; Abildgaard U
Thromb Res; 1992 Jun; 66(5):591-8. PubMed ID: 1523613
[TBL] [Abstract][Full Text] [Related]
16. Coagulation factors and antithrombin levels in young and elderly subjects in Pakistani population.
Amin H; Mohsin S; Aslam M; Hussain S; Saeed T; Ullah MI; Sami W
Blood Coagul Fibrinolysis; 2012 Dec; 23(8):745-50. PubMed ID: 23135380
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of potentiation of antithrombin III and heparin cofactor II inhibition by sulfated xylans.
Carson L; Doctor VM
Thromb Res; 1990 May; 58(4):367-81. PubMed ID: 1972302
[TBL] [Abstract][Full Text] [Related]
18. [Activities of antithrombin III and heparin cofactor II in patients with pathologic blood coagulation conditions].
Hirokawa S; Kaji T; Tazawa K; Fujimaki M; Hayashi T; Niiya K; Sakuragawa N
Rinsho Ketsueki; 1992 Mar; 33(3):281-7. PubMed ID: 1578630
[TBL] [Abstract][Full Text] [Related]
19. [Role of newly developed technology in blood coagulation disorders].
Matsuo T
Rinsho Byori; 2002 May; 50(5):506-12. PubMed ID: 12078050
[TBL] [Abstract][Full Text] [Related]
20. Thrombin-based antithrombin assays show overestimation of antithrombin III activity in patients on heparin therapy due to heparin cofactor II influence.
Bohner J; von Pape KW; Blaurock M
Thromb Haemost; 1994 Mar; 71(3):280-3. PubMed ID: 8029789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
